Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q3

3151.TEDINET S100SUKH
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥448.9bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥581.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥444.4bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥5.7bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥3.1bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥6.5bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥6.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.3bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥7.6bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥4.1bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥5.1bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥5.1bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥2.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥328.3bnat 2023-12-31Cons.Assets
Total assets¥297.3bnat 2023-03-31Cons.Assets
Total assets¥336.1bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥225.6bnat 2023-12-31Cons.Liabilities
Total liabilities¥197.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥102.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥100.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥102.4bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥31.1bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥19.0bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥99.122023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥53.662023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.692022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.592022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.222022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.9%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio30.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥4.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥2.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31−¥162m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥10.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥10.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31¥61m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2023-04-01 → 2023-12-31¥431.3bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2023-04-01 → 2023-12-31¥423.2bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2023-04-01 → 2023-12-31¥5.2bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥14.3bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥14.3bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥9m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥259m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥8.5bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥8.5bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥288m
—segment totalrevenue2023-04-01 → 2023-12-31¥454.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥446.0bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥8.0bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥5.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥458.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥448.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥10.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥5.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥4.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥3.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥236m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥126m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-12-31¥427.4bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-12-31¥419.4bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-12-31¥2.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥6m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥77m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥283m
—segment totalrevenue2022-04-01 → 2022-12-31¥449.4bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥441.4bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥3.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥454.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥444.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥9.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 377
ItemContextValueUnit
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember283000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember3171000000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-236000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember2935000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember126000000JPY
Operating incomePrior1YTDDuration3061000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember423218000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember14295000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember8472000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember445987000000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember2922000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember448909000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration448909000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember8031000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember9000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember0JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember8041000000JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1955000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9997000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-9997000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember431250000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember14304000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember8473000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember454028000000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember4878000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember458907000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-9997000000JPY
Net salesCurrentYTDDuration448909000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember5211000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember259000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember288000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember5759000000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-162000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember5597000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember61000000JPY
Operating incomeCurrentYTDDuration5658000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-02-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第15期第３四半期(自 2023年10月１日 至 2023年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社バイタルケーエスケー・ホールディングス
Company name in english cover pageFilingDateInstantVITAL KSK HOLDINGS, INC.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　村　井　泰　介
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区弦巻一丁目１番12号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)(03)5787－8550(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)執行役員経営企画部長　　高　橋　喜　春
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区弦巻一丁目１番12号

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass